Related Experiment Video
Updated: May 12, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
PandaOmics: An AI-Driven Platform for Therapeutic Target and Biomarker Discovery
Petrina Kamya1, Ivan V Ozerov2, Frank W Pun2
1Insilico Medicine Canada Inc., 3710-1250 René-Lévesque Blvd. W, Montreal, Quebec, Canada H3B 4W8.
Abstract:
PandaOmics is a cloud-based software platform that applies artificial intelligence and bioinformatics techniques to multimodal omics and biomedical text data for therapeutic target and biomarker discovery. PandaOmics generates novel and repurposed therapeutic target and biomarker hypotheses with the desired properties and is available through licensing or collaboration. Targets and biomarkers generated by the platform were previously validated in both in vitro and in vivo studies. PandaOmics is a core component of Insilico Medicine's Pharma.ai drug discovery suite, which also includes Chemistry42 for the de novo generation of novel small molecules, and inClinico─a data-driven multimodal platform that forecasts a clinical trial's probability of successful transition from phase 2 to phase 3. In this paper, we demonstrate how the PandaOmics platform can efficiently identify novel molecular targets and biomarkers for various diseases.
Related Concept Videos
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Drug Discovery: Overview
Pharmacogenomics: Identification of New Drug Targets
Steps in Outbreak Investigation
Microorganisms in Medicine and Therapeutics
Human Virome

